Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVX NASDAQ:KOD NYSE:QGEN NASDAQ:TGTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$99.15$114.06$5.69▼$148.83$7.91B0.693.00 million shs1.70 million shsKODKodiak Sciences$36.14$38.72$3.43▼$47.84$2.26B2.21684,070 shs1.21 million shsQGENQiagen$37.00+0.1%$36.68$32.53▼$57.81$7.61B0.662.11 million shs1.96 million shsTGTXTG Therapeutics$53.22$40.19$25.28▼$54.07$8.15B1.682.36 million shs7.16 million shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax0.00%+2.69%-17.31%-17.61%+1,538.84%KODKodiak Sciences0.00%+6.11%-0.22%+62.28%+923.80%QGENQiagen0.00%-0.19%+5.52%-7.35%-24.47%TGTXTG Therapeutics0.00%+7.47%+33.85%+76.91%+51.32%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$99.15$114.06$5.69▼$148.83$7.91B0.693.00 million shs1.70 million shsKODKodiak Sciences$36.14$38.72$3.43▼$47.84$2.26B2.21684,070 shs1.21 million shsQGENQiagen$37.00+0.1%$36.68$32.53▼$57.81$7.61B0.662.11 million shs1.96 million shsTGTXTG Therapeutics$53.22$40.19$25.28▼$54.07$8.15B1.682.36 million shs7.16 million shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax0.00%+2.69%-17.31%-17.61%+1,538.84%KODKodiak Sciences0.00%+6.11%-0.22%+62.28%+923.80%QGENQiagen0.00%-0.19%+5.52%-7.35%-24.47%TGTXTG Therapeutics0.00%+7.47%+33.85%+76.91%+51.32%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVXAbivax 2.73Moderate Buy$130.0831.19% UpsideKODKodiak Sciences 2.63Moderate Buy$42.1416.61% UpsideQGENQiagen 2.42Hold$44.9821.56% UpsideTGTXTG Therapeutics 2.71Moderate Buy$52.50-1.35% DownsideCurrent Analyst Ratings BreakdownLatest KOD, ABVX, QGEN, and TGTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2026ABVXAbivax BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$150.006/3/2026ABVXAbivax Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$136.006/3/2026ABVXAbivax Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/2/2026ABVXAbivax Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$140.00 ➝ $135.006/2/2026ABVXAbivax Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$145.00 ➝ $132.006/2/2026ABVXAbivax CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/2/2026ABVXAbivax Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$160.00 ➝ $90.006/2/2026ABVXAbivax Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$131.00 ➝ $187.006/2/2026ABVXAbivax WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderperform ➝ Neutral$110.00 ➝ $90.006/2/2026ABVXAbivax BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$150.006/1/2026TGTXTG Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold(Data available from 6/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVXAbivaxN/AN/AN/AN/A$6.57 per shareN/AKODKodiak SciencesN/AN/AN/AN/A$2.97 per shareN/AQGENQiagen$2.09B3.65$3.41 per share10.85$17.89 per share2.07TGTXTG Therapeutics$700.35M11.63$2.80 per share18.99$4.08 per share13.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVXAbivax-$380.27M-$5.21N/AN/AN/AN/A-99.02%-70.26%N/AKODKodiak Sciences-$229.97M-$4.17N/AN/AN/AN/A-253.85%-81.48%8/12/2026 (Estimated)QGENQiagen$424.88M$1.9119.3214.023.6819.16%14.40%8.40%8/4/2026 (Estimated)TGTXTG Therapeutics$447.18M$2.8618.6119.35N/A65.95%88.73%43.44%8/3/2026 (Estimated)Latest KOD, ABVX, QGEN, and TGTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/22/2026Q1 2026ABVXAbivax-$0.9359-$0.71+$0.2259-$0.71$0.40 million$1.56 million5/7/2026Q4 2025KODKodiak Sciences-$0.93-$0.94-$0.01-$0.94N/AN/A5/7/2026Q1 2026QGENQiagen$0.54$0.54N/A$0.33$496.15 million$492.32 million5/6/2026Q1 2026TGTXTG Therapeutics$0.23$0.12-$0.11$0.12$200.33 million$204.92 million3/31/2026Q4 2025KODKodiak Sciences-$1.02-$1.04-$0.02-$1.04N/AN/A3/23/2026Q4 2025ABVXAbivax-$2.24-$1.20+$1.04-$1.20$1.80 million$0.52 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABVXAbivaxN/AN/AN/AN/AN/AKODKodiak SciencesN/AN/AN/AN/AN/AQGENQiagen$0.260.70%N/A13.61%N/ATGTXTG TherapeuticsN/AN/AN/AN/AN/ALatest KOD, ABVX, QGEN, and TGTX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/11/2026QGENQiagenannual$0.351.04%7/7/20267/7/20267/14/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVXAbivaxN/A8.258.25KODKodiak SciencesN/A3.543.54QGENQiagen0.493.212.57TGTXTG Therapeutics1.285.815.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVXAbivax47.91%KODKodiak Sciences89.06%QGENQiagen70.00%TGTXTG Therapeutics58.58%Insider OwnershipCompanyInsider OwnershipABVXAbivaxN/AKODKodiak Sciences45.90%QGENQiagen9.00%TGTXTG Therapeutics8.87%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVXAbivax6179.77 millionN/ANot OptionableKODKodiak Sciences9062.58 million33.86 millionOptionableQGENQiagen5,654206.07 million187.53 millionOptionableTGTXTG Therapeutics290153.08 million139.51 millionOptionableKOD, ABVX, QGEN, and TGTX HeadlinesRecent News About These CompaniesIs TG Therapeutics, Inc. (TGTX) A Good Stock To Buy Now?June 19 at 1:30 PM | insidermonkey.comIs TG Therapeutics, Inc. (TGTX) A Good Stock To Buy Now?June 19 at 12:30 PM | finance.yahoo.comTG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Rating of "Moderate Buy" from BrokeragesJune 19 at 4:05 AM | americanbankingnews.comTG Therapeutics Stock Rises Thursday: What's Driving The Gains?June 18 at 3:29 PM | benzinga.comTGTX Stock Continues Rally For 8 Straight Sessions On New BRIUMVI Clinical DataJune 17 at 8:47 PM | msn.comTG Therapeutics stock is on a hot streak: Why it's up 70% and climbingJune 17 at 3:46 PM | msn.comTG Therapeutics (NASDAQ:TGTX) Hits New 52-Week High - Still a Buy?June 16, 2026 | americanbankingnews.comTG Therapeutics (NASDAQ:TGTX) Reaches New 12-Month High - Should You Buy?June 12, 2026 | americanbankingnews.comTG Therapeutics, Inc. $TGTX Shares Sold by WINTON GROUP LtdJune 11, 2026 | marketbeat.comTG Therapeutics (TGTX) Soars 7.5%: Is Further Upside Left in the Stock?June 11, 2026 | zacks.comWhy TG Therapeutics (TGTX) Is Up 18.4% After Advancing At‑Home Subcutaneous BRIUMVI In MS TreatmentJune 10, 2026 | finance.yahoo.comTGTX Rises on Positive Phase I Data for Subcutaneous Briumvi in MGJune 10, 2026 | zacks.comTGTX Stock Jumps 5% On Positive Early Data For At-Home BRIUMVI In Muscle DiseaseJune 10, 2026 | finance.yahoo.comTG Therapeutics, Inc. (TGTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 9, 2026 | seekingalpha.comTG Thera posts early-stage data for Briumvi in myasthenia gravis; launches mid-stage trialJune 9, 2026 | seekingalpha.comTG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized ...June 9, 2026 | finance.yahoo.comA Look At TG Therapeutics (TGTX) Valuation After Recent Positive BRIUMVI Trial UpdatesJune 9, 2026 | finance.yahoo.comTG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 TrialJune 9, 2026 | globenewswire.comB. Riley Securities Remains a Buy on TG Therapeutics (TGTX)June 8, 2026 | theglobeandmail.comWhy Is TG Therapeutics (TGTX) Down 5.7% Since Last Earnings Report?June 5, 2026 | zacks.comTG Therapeutics rises on early-stage trial data for Briumvi injectableJune 4, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKOD, ABVX, QGEN, and TGTX Company DescriptionsAbivax NASDAQ:ABVX$99.15 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$100.00 +0.85 (+0.86%) As of 06/18/2026 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.Kodiak Sciences NASDAQ:KOD$36.14 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$35.49 -0.65 (-1.80%) As of 06/18/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.Qiagen NYSE:QGEN$37.00 +0.05 (+0.14%) Closing price 06/18/2026 03:59 PM EasternExtended Trading$36.97 -0.03 (-0.09%) As of 06/18/2026 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.TG Therapeutics NASDAQ:TGTX$53.22 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$52.93 -0.29 (-0.55%) As of 06/18/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/15 - 06/19 Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Why Kroger’s Pullback Could Be a Gift for Patient Investors Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate VMware: Broadcom's Second Biggest Business Set to Accelerate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
